GIANT CELL ARTERITIS (GCA)
Clinical trials for GIANT CELL ARTERITIS (GCA) explained in plain language.
Never miss a new study
Get alerted when new GIANT CELL ARTERITIS (GCA) trials appear
Sign up with your email to follow new studies for GIANT CELL ARTERITIS (GCA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug may help patients with rare artery disease taper steroids faster
Disease control CompletedThis study tested a drug called secukinumab in 354 people with giant cell arteritis, a condition where blood vessels become inflamed. The goal was to see if secukinumab could help patients achieve remission while reducing their need for steroids. Participants received either secu…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 09:29 UTC
-
New pill may help patients with rare artery disease ditch steroids faster
Disease control CompletedThis study tested a drug called upadacitinib in 429 people with giant cell arteritis, a condition that causes inflamed arteries. The goal was to see if the drug could help patients achieve remission while using steroids for a shorter time. Results showed that upadacitinib combine…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Which drug better protects GCA patients from heart attacks and strokes?
Knowledge-focused CompletedThis study looked at two medications, tocilizumab and methotrexate, to see which one better prevents major heart problems like heart attacks, strokes, or death in people with giant cell arteritis (GCA). Researchers analyzed data from over 1,600 patients in France who were newly t…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Sponsor: Groupe français d'étude des Maladies Inflammatoires de loeil • Aim: Knowledge-focused
Last updated May 22, 2026 13:53 UTC